Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth and Accelerate Innovation in Long-Acting Therapies

"Dr. Ron combines unmatched scientific expertise combined with a track record of effective business leadership, making him a key driver of innovation and growth at AmacaThera." said Dr. Mike Cooke, CEO of AmacaThera. "His exceptional ability to foster innovation, establish strategic partnerships, lead business development initiatives, and provide strong governance will be instrumental in advancing the Company's strategic goals and accelerating the development of groundbreaking therapies. His appointment reinforces AmacaThera's commitment to scaling its transformative platform technology, AmacaGel™, to meet the needs of patients globally."

About AmacaThera

AmacaThera is a clinical-stage biotechnology company focused on advanced sustained-release hydrogel formulations designed to address critical challenges in therapeutic drug delivery. The Company's flagship platform, AmacaGel™, enables the development of long-acting therapies that enhance patient outcomes while minimizing systemic side effects. AmacaThera is driving innovation in key therapeutic areas, including pain management and oncology.

The Company's lead product, AMT-143, is currently advancing into Phase 2 clinical trials. It has demonstrated best-in-class pharmacokinetics, showing strong potential to as an alternative to opioid-based solutions in post-operative pain management.

AmacaThera's proprietary AmacaGel™ platform is a fast-gelling physical hydrogel composed of two well-established polymers. Designed to liquefy under shear force, AmacaGel can be delivered via a conventional syringe and rapidly forms a depot as it warms to body temperature. The platform's lead asset, AMT-143, is a slow-release, non-opioid local anesthetic that leverages the AmacaGel technology to provide long-acting post-operative pain relief.

AmacaThera is backed by prominent investors, including Lumira Ventures, BDC Capital, StandUp Ventures, MaRS IAF, and Changrong Capital.

About Dr. Eyal S. Ron

Dr. Eyal S. Ron has a proven track record of elevating biotech startups and steering them toward successful exits while delivering impactful solutions to patients and stakeholders. He played a critical role in developing cutting-edge products, including sustained-release oral dosage forms (Perfusia^® and Plenity™), implantable biodegradable sustained-release devices (Gliadel^®, Nutropin Depot^®, InFuse^®, and ProLease^®), and biodegradable sealants (FocalSeal^®). Dr. Ron has driven numerous companies to success, achieving exits valued at over $1 billion.

For more information, visit www.amacathera.ca.

Media Contact: Michael J. Cooke, CEO and Co-Founder, [email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/dr-eyal-s-ron-joins-amacathera-board-of-directors-to-drive-strategic-growth-and-accelerate-innovation-in-long-acting-therapies-302345120.html